JP2017508442A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508442A5
JP2017508442A5 JP2016546862A JP2016546862A JP2017508442A5 JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5 JP 2016546862 A JP2016546862 A JP 2016546862A JP 2016546862 A JP2016546862 A JP 2016546862A JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5
Authority
JP
Japan
Prior art keywords
genes listed
derivative
mdm2i
salt
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/051157 external-priority patent/WO2015108175A1/en
Publication of JP2017508442A publication Critical patent/JP2017508442A/ja
Publication of JP2017508442A5 publication Critical patent/JP2017508442A5/ja
Pending legal-status Critical Current

Links

JP2016546862A 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー Pending JP2017508442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927310P 2014-01-14 2014-01-14
US61/927,310 2014-01-14
PCT/JP2015/051157 WO2015108175A1 (en) 2014-01-14 2015-01-13 Gene signatures associated with sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017508442A JP2017508442A (ja) 2017-03-30
JP2017508442A5 true JP2017508442A5 (enExample) 2018-02-08

Family

ID=52432889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546862A Pending JP2017508442A (ja) 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー

Country Status (4)

Country Link
US (1) US20160333419A1 (enExample)
EP (1) EP3094746A1 (enExample)
JP (1) JP2017508442A (enExample)
WO (1) WO2015108175A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
SG193002A1 (en) 2011-03-10 2013-09-30 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TWI750129B (zh) * 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
TW202332444A (zh) * 2015-10-23 2023-08-16 日商第一三共股份有限公司 用於治療癌症之醫藥組成物
JP2018538247A (ja) * 2015-10-23 2018-12-27 第一三共株式会社 Amlを処置することに用いるための医薬組成物およびそれを必要とする対象においてamlを処置する方法
CN106512009B (zh) * 2016-10-28 2019-10-11 武汉大学 Ph同源域家族a成员3(phlda3)在治疗心肌肥厚中的应用
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
JP7638527B2 (ja) * 2019-05-23 2025-03-04 国立大学法人大阪大学 性ホルモン非感受性greb1陽性腫瘍の治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742285T3 (es) * 2012-07-31 2020-02-13 Novartis Ag Marcadores asociados con la sensibilidad a inhibidores del doble minuto humano 2 (MDM2)
SG11201510816SA (en) * 2013-07-03 2016-01-28 Hoffmann La Roche Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Similar Documents

Publication Publication Date Title
JP2017508442A5 (enExample)
CN112930569B (zh) 无细胞dna中的微卫星不稳定性检测
Schlauch et al. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome
ES2577289T3 (es) Calreticulina mutante para el diagnóstico de malignidades mieloides
Bilke et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
JP2013127477A5 (enExample)
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Noviello et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
EP4574992A3 (en) Combinatorial dna screening
JP2017523810A5 (enExample)
JP2016532689A5 (enExample)
JP2017512491A5 (enExample)
JP2025026905A (ja) ヒト腫瘍のがん細胞における分子活性を定量化するための方法
JP2016000057A5 (enExample)
JP2017532959A5 (enExample)
JP2011528903A5 (enExample)
JP2017509351A5 (enExample)
Ju et al. Identification of a miRNA-mRNA network associated with lymph node metastasis in colorectal cancer
US20150071946A1 (en) Tumor-specific retrotransposon insertions
RU2009127735A (ru) Определение предрасположенности к раку путем идентификации генотипических комбинаций специфичных вариантов генов cyp1b1, brca2 и снек2
KR20170072685A (ko) 삼중음성유방암의 아형 분류 방법
CN111480079A (zh) 疾病蛋白质组蛋白质阵列及其应用
Huang et al. Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing
CN103114138A (zh) Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒
RU2621161C1 (ru) Способ диагностики гликогеновой болезни IXa типа у детей с использованием технологии секвенирования нового поколения